(CTN News) – AbbVie made public the topline findings of Phase II PICCOLO research on Thursday, the day the research was conducted. These findings offer evidence that the recently acquired antibody-drug combination Elahere (mirvetuximab and soravtansine) from ImmunoGen has the potential to be used as a therapeutic agent in the treatment of folate receptor-alpha-positive, AbbVie […]

The post AbbVie’s $10B Immunogen Purchase Gets Early ROI With Phase II Ovarian Cancer Win appeared first on CTN News – Chiang Rai Times.

Go to Source
Author: AlishbaW